Asta Medica, Aktiengesellschaft

Spectrum Pharmaceuticals, Inc.

Asta Pharma Aktiengesellschaft

Zentaris Gmbh

Zentaris Ag

Meda Pharma Gmbh & Co. Kg

Zentraris Gmbh

Juergen Engel

Sabine Heer

Matthias Rischer

Horst Mueller

Karl Werner

Istvan Szelenyi

Peter Emig

Bernd Nickel

Dieter Sauerbier

Gerhard Scheffler

Peter Hilgard

Degenhard Marx

Thomas Klenner

Hildegard Kuss

Werner Sarlikiotis

Eckhard Milsmann

Carl H Weischer

Istvan Szelenyl

The invention relates to methods of treatment or prophylaxis of physiological and/or pathological conditions with at least one LHRH antagonist, in particular at least one peptidomimetic LHRH antagonist such that the at least one LHRH antagonist is administered in a dose, which does not cause chemical (hormonal) castration.

Use of LHRH antagonists for intermittent treatments

The invention provides sterile suspensions and sterile lyophilizates of slightly soluble basic peptide complexes, and pharmaceutical formulations comprising them. The provided sterile suspensions, sterile lyophilizates and pharmaceutical formulations comprising them are particularly suitable for use in a parenteral dosage form as medicaments for the treatment and prophylaxis of diseases and pathological states in mammals, especially in humans.

Sterile suspensions of slightly soluble basic peptide complexes and pharmaceutical formulations containing them

The present invention provides a novel process for producing sterile suspensions of slightly soluble basic peptide complexes. The present invention further provides a novel process for producing sterile lyophilizates of slightly soluble basic peptide complexes. In addition, a novel process for producing sterile suspensions suitable for the parenteral administration of slightly soluble basic peptide complexes is provided. The invention moreover provides sterile suspensions and sterile lyophilizates of slightly soluble basic peptide complexes, and pharmaceutical formulations comprising them. The provided sterile suspensions, sterile lyophilizates and pharmaceutical formulations comprising them are particularly suitable for use in a parenteral dosage form as medicaments for the treatment and prophylaxis of diseases and pathological states in mammals, especially in humans.

Process for producing sterile suspensions of slightly soluble basic peptide complexes, sterile suspensions of slightly soluble basic peptide complexes, pharmaceutical formulations containing them, and the use thereof as medicaments

The invention relates to a novel combination of a soft steroid, in particular loteprednol, and at least one &#x3b2;adrenoceptor agonist for the simultaneous, sequential or separate treatment of allergies and/or airway disorders, medicaments comprising the combination, processes for the production of such medicaments and the use of the novel combination for the production of medicaments for the simultaneous, sequential or separate treatment of allergies and/or airway disorders.

[object Object]

The present invention relates to a novel combination of a soft steroid, in particular loteprednol, and at least one antihistamine, such as, for example, azelastine and/or levocabastine, for simultaneous, sequential or separate administration in the local treatment of allergies and airway disorders, for example of allergic rhinitis (rhinoconjunctivitis).

Combination of loteprednol and antihistamines

The present invention relates to new solid pharmaceutical compositions containing hexadecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis, a process for the manufacture of said pharmaceutical composition, a dosage scheme for oral administration of said pharmaceutical composition in the treatment of leishmaniasis, and finally a combination comprising said solid pharmaceutical composition, antiemeticum, and/or an antidiarrhoeal.

Solid pharmaceutical compositions containing hexedecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis

2,6-diamino-3-halobenzylpyridines of the formula I: ##STR1## wherein R.sub.1 is fluorine and R.sub.2 is hydrogen or chlorine as well as their physiologically acceptable acid addition salts, processes for their manufacture and their use in pharmaceuticals.

2,6-diamino-3-halobenzylpyridines and processes for their manufacture as

Growing community of inventors

Alzenau, Germany

Juergen Engel